Johnson and Johnson 2012 Annual Report Download - page 8

Earlier in the year, Ethicon Endo-Surgery, Inc. received an approvable letter for the SEDASYS®System, a
computer-assisted personalized sedation system, from the FDA’s Center for Devices and Radiological Health. In
addition, Biosense Webster’s THERMOCOOL®SMARTTOUCH™Contact Force Sensing Catheter received CE
Mark clearance in Europe. The catheter provides real-time information about the precise amount and direction of
the force being applied during cardiac ablation procedures.
We’re expanding our global presence with strong growth in emerging markets. And as we look to the future,
we’re advancing innovative new products in our pipeline, continuing to take a disciplined approach to managing
our portfolio and adapting our business to the changing marketplace.
CONSUMER
With $14.4 billion in worldwide sales in 2012, our Consumer business is the sixth-largest consumer health care
business in the world. Operational growth was 0.5 percent. We remain committed to strengthening the Consumer
business starting by continuing to restore a reliable supply of our McNeil over-the-counter (OTC) products to the
U.S. market.
Meanwhile, positive contributors to operational results were sales of upper respiratory OTC products outside
the U.S.; international sales of LISTERINE®oral care products; and U.S. sales of NEUTROGENA®skin care
products.
Our investments for growth in Consumer will be predicated on a focused product portfolio approach to deliver
science-based products with local market insights, professional endorsements and commercial excellence.
We have taken steps to reshape our portfolio and have divested non-strategic products or brands. We are also
investing in growth and expansion in emerging markets through the acquisition of market-specific brands like
DOKTOR MOM®cough cold products in Russia and Shanghai Elsker Mother & Baby Co. Ltd. in China. We’re
also continuing to leverage the strength of our iconic brands like JOHNSON’S®Baby and NEUTROGENA®.
Regarding McNeil, we’re continuing to operate in accordance with the consent decree. We’ve achieved all
commitments to date under the remediation work plan, which was approved by the FDA in 2012. The work to
bring our plants fully online is progressing. We expect to return to a consistent supply of key products to the
market over the course of 2013. Our efforts continue to be in the interest of serving customers, consistent with the
responsibilities outlined in Our Credo.
NOTE ON FORWARD-LOOKING STATEMENTS
This Annual Report contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited
to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations;
technological advances, new products and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approvals; significant adverse litigation or government action; impact of business combinations;
changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to
governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment;
increased scrutiny of the health care industry by government agencies; manufacturing difficulties or delays; and product efficacy
or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and
other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended
December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available on-line at www.sec.gov,
www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any
forward-looking statements as a result of new information or future events or developments.
2012 BUSINESS SEGMENT HIGHLIGHTS